DIA Biosimilars 2013

Paladin Labs

QRxPharma inks strategic collaboration with Paladin Labs

Wednesday, October 10, 2012 11:31 AM

QRxPharma, a commercial-stage specialty pharmaceutical company based in Bedminster, N.J., signed a licensing agreement with Paladin Labs, specialty pharmaceutical company based in Montreal, for the Canadian commercialization rights to Moxduo, a patented, immediate-release formulation of morphine and oxycodone. 

More... »

Cenduit: Now with Patient Reminders

Paladin partners with Litha, aid merge of South African pharmas

Thursday, February 23, 2012 06:30 AM

Montreal-based Paladin Labs has formed a strategic partnership to accelerate its buyout of the remaining shares of South Africa-based Pharmaplan and merge the business with the pharma division of Litha Healthcare Group, based in South Africa.

More... »

CRF Health – eCOA Forum

Valeant to acquire Afexa Life Sciences

Wednesday, August 31, 2011 12:25 PM

Valeant Pharmaceuticals International has agreed to acquire fellow Canadian firm Afexa Life Sciences for $76 million in cash, a figure that comfortably tops an offer made by another company based in Canada, Paladin Labs, according to PharmaTimes.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs